Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Ceutics Exam 2 > Topical dosage forms and transdermal drug delivery > Flashcards

Topical dosage forms and transdermal drug delivery Flashcards

1
Q

How many transdermal patches are currently manufactured each year?

A

It is estimated that more than one billion are currently manufactured each year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the layers of the skin?

A

Stratum corneum
Epidermis
Dermis
Subcutaneous

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the stratum corneum? What are its features?

A
  • 10 um in thickness
  • 15-25 layers of flattened corneocytes
  • tightly packed cells protect the body from harmful material and from water loss
  • drugs penetrate this layer by passive diffusion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the composition of the stratum corneum?

A
  • 40% protein
  • 40% water
  • triglycerides, cholesterol, and phospholipids
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Why wouldn’t you want to put a patch on bruised or damaged areas of the skin?

A

because the devices in the patch have membranes that control the rate the substance penetrates the skin, if the skin is damaged the drug may go very rapidly through these areas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Why is the lipid component of the skin an important determinant in the absorption process of a patch?

A
  • the majority of lipid is stored in the extracellular phase in the membrane surrounding cells
  • and a drug’s major route of penetration is through the intercellular channels
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is a drug’s major route of penetration?

A

through the intercellular channels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What does the reate of drug movement depend on?

A
  • concentration in the vehicle
  • aqueous solubility
  • oil- water partition coefficient between stratum corneum
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What would be an issue with a purely lipophilic drug in a patch?

A

The dosage form may have high affinity but when you apply the patch to the skin the drug doesn’t leave the patch

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Why does a drug need some hydrophilic (aqueous) and some lipophilic character?

A

so it can penetrate layers of the skin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what do transdermal drug delivery systems do?

A

they facilitate the passage of therapeutic quantities of drug substances through the skin, and into the general circulation for their systemic effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Why are chemical enhancers important in patches?

A
  • chemical enhancers improve percutaneous absorption
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are some chemical enhancers?

A
  • acetone
  • azone
  • poly-ethylene glycol
  • DMSO (used for many different things - freeze cells and go back and use them later, in TDDS we are trying to get it to improve absorption by the skin)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How does 60% DMSO alter proteins and lipids in the skin?

A
  • Low DMSO - not effective - didn’t alter fluid properties of membrane (lipids), did alter keratin
    •High DMSO - membrane fluidity and keratin altered - improves percutaneous absorpt
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are some things necessary for a TDDS?

A
  • needs efficacy in enhancing skin permeation (can’t manage condition if drug isn’t getting through skin)
  • must have low toxicity ( don’t want toxic because they usually have a low toxic effect - benefit of patches)
  • must be biocompatible
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are some indicators that the TDDS is working (i.e. percutaneous absorption is occurring)?

A
  • measurable blood levels of the drug
  • detectable excretion of the drug
  • clinical response of the patient
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

When was the first TDDS approved by the FDA? What was it?

A
  • 1979

- scopalamine was used to prevent nausea and vomiting associated with travel mainly by sea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What were characteristics of the first TDDS dosage form?

A
  • circular patch (0.2mm thick)
  • 1.5 mg of drug ( a belladonna alkaloid - bad taste) - only 1.5 mg of drug - if drug isn’t potent won’t be effective in patch
  • delivers 1/4 mg of drug at a constant rate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are the melting point and molecular weight of scopalamine?

A

303

59 degrees celsius

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What enhancers could be used for scopalamine? (what is it soluble in?

A

hot water, alcohol, ether, chloroform and acetone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Where doest the drug go through before it enters your stratum corneum (skin)?

A

the patch membrane - has to go through two membranes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What controls the rate of absorption of scopalamine? Why?

A

The membrane (not the skin) controls the rate of absorption because the rate that the drug is released is less than the skin’s ability to absorb

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

If the rate in which drug substance penetrate the skin is slower than the rate at which the drug travels through the patch reservoir and semipermeable membrane, the

A

skin controls the absorption rate

*** The slower step is the rate limiting factor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

If the rate in which the drug substance travels through the patch reservoir and semipermeable membrane is slower than the rate the drug substance penetrate the layers of the skin,

A

then the semipermeable membrane is the rate limiting step, not the skin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What are the factors that affect percutaneous absorption?

A
  • physical and chemical properties of the skin
  • molecular weight ( use a chemical enhancer if you need to use high weight)
  • solubility and pka
  • partitioning coefficient (hydrophilic or lipophilic)
  • nature of the carrier vehicle ( how it communicates with skin layers)
  • condition of the skin
26
Q

how is the condition of the skin affected?

A
  • age
  • temperature (if very hot or cold outside the patch may be more effected than your skin)
  • site of administration (percutaneous absorption much slower on heel of foot)
  • race (pigmentation - dark and white skin) - stratum corneum more layers in darker skin - melanocytes no real absorption effect
  • disease (i.e. psoriasis)
27
Q

What molecular weights are favored for patches?

A

between 100 and 800

28
Q

What does a monolithic TDDS system incorporate?

A

a drug matrix layer between backing and frontal layers

- polymeric material controls rate of drug release, so it is often used in monolithic systems

29
Q

What are the two types of monolithic systems

A
  1. with excess drug inside the matrix: drug reserve is used to assure continued drug saturation
  2. without excess drug: used to maintain saturation at the stratum corneum layer, only (want to have stratum corneum saturated)
30
Q

How is a monolithic system prepared?

A
  • the drug and polumer are both dissolved or blended together, cast as a matrix and dried
31
Q

Most monolithic systems are designed to contain an excess or not contain an excess of drug?

A

MOST are designed to contain an excess of the drug, and thus have drug - releasing capacity beyond the time frame recommended for replacement

32
Q

What are membrane- controlled transdermal systems designed to contain?

A

They are designed to contain a drug reservoir or “pouch” usually in liquid or gel form, a rate-controlling membrane, and backing, adhesive and protecting layers

33
Q

What is the advantage of membrane- controlled transdermal systems over monolithic systems?

A

As long as the drug in the reservoir system remains saturated, the drug release remains constant

34
Q

How is a membran- controlled transdermal system prepared?

A

the delivery unit is added to the drug reservoir, and sealed by a process called lamination
**either the drug delivery system, OR the skin may serve to control drug release

35
Q

What are chemical methods used to enhance drug delivery and penetration?

A

They are chemicals that increase skin permeability by reversibly damaging or by altering the physicochemical nature of the stratum corneum to reduce its diffusional resistance

36
Q

How do chemical methods reduce the diffusional resistance of the stratum corneum?

A
  • increased hydration of the stratum corneum or

- change properties of lipids and proteins

37
Q

What are examples of chemicals used to enhance drug delivery and penetration?

A

DMSO, ethanol, polyethylene glycol

**always select enhancers with knowledge of their toxicity

38
Q

What are the two physical methods used to enhance drug delivery and penetration?

A

ionotophoresis and sonophoresis

39
Q

What is ionotophoresis?

A
  • an applied electric field is used to deliver chemicals across the skin membrane **drug needs to be inionic form
40
Q

What are the mechanisms for ionotophoresis for a drug to deliver chemicals across the skin membrane?

A
  • ionic electric field interaction
  • increased permeability
  • electroosmosis produces bulk motion of solvent
41
Q

What are example of ionotophoresis

A

dexamethasone and verapamil

42
Q

What is sonophoresis?

A

high frequency ultrasound used to deliver chemicals across the skin membrnae - chemical enhancers may not be necessary

43
Q

What are examples of sonophoresis?

A

hydrocortisone and salicylic acid used in gels, creams and lotions

44
Q

What is the small direct current used to transport charged drug molecules into and through tissues passed through

A

It passes through a drug - containing active electrode in contact with skin

45
Q

What can ionotophoresis be used to treat?

A

areas of inflammation such as tendonitis

- can be used as an alternative to procedures that are more invasive

46
Q

Is ionotophoresis or a monolithic system more efficient?

A

ionotophoresis

47
Q

What are advantages of sonophoresis?

A
  • compounds don’t need to be ionized
  • more effective than topical applications alone
  • cavitation (ocurring in keratinocytes) gave rise to better penetration of vitamin A within cells, stimulating mRNA and this produced faster growth of keratinocytes and collagen production
48
Q

What is transderm-nitro (novartis)? What is is used to provide? What does it treat? Where is it applied

A

Transderm-nitro is nitroglycerin
It is used to provide controlled release of nitroglycerin
It is used to treat angina
Is is applied to the chest and upper arm of shoulder areas

49
Q

What is scopalamine used for? What does it treat? Where is it applied

A

used to provide controlled release or scopolamine over 3 day period

  • it treats nausea related to travel by sea
  • it is applied behind the ear, once patch removed and another can be applied when desireable
50
Q

What is the backing of transderm nitro made of?

What is the backing of transderm scop made of?

A

transderm nitro is aluminized plastic

Transderm scop is aluminized polyester film

51
Q

What is the drug reservoir content of transderm nitro (novartis)?

A

nitroglycerin adsorbed on lactose, colloidal silicon dioxide, and silicone medical fluid

52
Q

What are the drug reservoir contents of transderm scop?

A

scopalamine, mineral oil, and polyisoobutylene (Mw 303, viscous liquid)

53
Q

What is the dose, treatment, and application of transdermal nicotine?

A

Dose: 7 to 22 mg of nicotine/day
Treatment: 6-8 wks, replace daily, disscard after use
Where applied: arm or upper front torso

54
Q

What is the dose, and treatment of transdermal estradiol?

A

Dose: 0.05 or 0.1 mg estradiol per day
Treatment: 3 weeks of treatment followed by one w/o and so forth
- patients are provided with 17 beta estradiol for conditions associated with menopoause, primary ovarian failure, etc.

55
Q

Why is oral delivery of estradiol a problem?

A

because it is converted to estrone which is inactive

56
Q

What are advantages of TDDS?

A
  • can avoid difficulties with gastrointestinal drug absorption
  • can be used as a substitute for oral administration of medication
  • can avoid first- pass elimination
  • the systems are non-invasive
  • can provide extended therapy with a single application
  • drugs with a short half life can be extended through the reservoir
  • drug therapy may be terminated by removing application from skin surface
  • ease of rapid identification of the medication in emergency situations
57
Q

What are disadvantages of TDDS?

A
  • only potent drugs are considered suitable candidates because only low plasma levels of drug can be maintained
  • some patients may develop severe response to treatment at the site of application (i.e. dermatitis) in such cases treatments are usually terminated or a different area is used
58
Q

What are some general considerations in the use of TDDS?

A
  • extent of percutaneous absorption may vary according to site of application
  • TDDSs should be applied to very clean, dry skin areas
  • use of skin lotions should be avoided ( will alter absorption)
  • TDDs should not be physically altered in any way
  • be careful not to damage TDDS when removing from package
59
Q

What should be discussed with patients about TDDS?

A
  • apply to areas not likelyt to be rubbed off by clothing
  • must be worn for the full period of time as discussed in packing insert
  • use clean hands when applying and removing TDDS
  • always seek medical advice to sensitivity or any intolerance to the TDDS
  • remove the patch when finished and discard as recommended
  • keep away from children
60
Q

What happens if the condition to treat is located in the skin? For melanoma: can you get enough drug through the skin from the patch to treat?

A

may surgically remove the tumor and then apply the patch with chemotherapeutic function and deal with residual disease

Ceutics Exam 2 (3 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions